期刊
CELL
卷 184, 期 18, 页码 4651-+出版社
CELL PRESS
DOI: 10.1016/j.cell.2021.08.002
关键词
-
资金
- National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD) - NIA [U24 AG021886]
- NIA
- NINDS
- ARTFL [U54 NS092089]
- NCATS
Mutations in the GRN gene lead to frontotemporal dementia, with a deficiency in the PGRN protein being the cause. Research found various abnormalities in Grn(-/-) mice, including a lack of endolysosomal phospholipids and accumulation of glucocerebrosidase substrate. A protein replacement strategy corrected these abnormalities and may represent a potential biotherapeutic for GRN-FTD.
GRN mutations cause frontotemporal dementia (GRN-FTD) due to deficiency in progranulin (PGRN), a lysosomal and secreted protein with unclear function. Here, we found that Grn(-/-) mice exhibit a global deficiency in bis(monoacylglycero)phosphate (BMP), an endolysosomal phospholipid we identified as a pH-dependent PGRN interactor as well as a redox-sensitive enhancer of lysosomal proteolysis and lipolysis. Grn(-/-) brains also showed an age-dependent, secondary storage of glucocerebrosidase substrate glucosylsphingosine. We investigated a protein replacement strategy by engineering protein transport vehicle (PTV):PGRN-a recombinant protein linking PGRN to a modified Fc domain that binds human transferrin receptor for enhanced CNS biodistribution. PTV:PGRN rescued various Grn(-/-) phenotypes in primary murine macrophages and human iPSC-derived microglia, including oxidative stress, lysosomal dysfunction, and endomembrane damage. Peripherally delivered PTV:PGRN corrected levels of BMP, glucosylsphingosine, and disease pathology in Grn(-/-) CNS, including microgliosis, lipofuscinosis, and neuronal damage. PTV:PGRN thus represents a potential biotherapeutic for GRN-FTD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据